{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T13:04:36Z","timestamp":1781096676137,"version":"3.54.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":245,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1124\/dmd.123.001607","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T19:15:14Z","timestamp":1710443714000},"page":"355-367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetic Effects of Different Models of Nonalcoholic Fatty Liver Disease in Transgenic Humanized OATP1B Mice"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4287-1877","authenticated-orcid":false,"given":"Baron J.","family":"Bechtold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine D.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7351-3358","authenticated-orcid":false,"given":"Victoria O.","family":"Oyanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Ridge","family":"Call","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler N.","family":"Graf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas H.","family":"Oberlies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3835-7761","authenticated-orcid":false,"given":"John D.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.123.001607_bib1","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/cpt.997","article-title":"Transporter-mediated alterations in patients with NASH increase systemic and hepatic exposure to an OATP and MRP2 substrate","volume":"104","author":"Ali","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.123.001607_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.tox.2021.153021","article-title":"MCLR-elicited hepatic fibrosis and carcinogenic gene expression changes persist in rats with diet-induced nonalcoholic steatohepatitis through a 4-week recovery period","volume":"464","author":"Arman","year":"2021","journal-title":"Toxicology"},{"key":"10.1124\/dmd.123.001607_bib3","doi-asserted-by":"crossref","first-page":"29127","DOI":"10.1074\/jbc.M110.169771","article-title":"Unfolded protein response is required in nu\/nu mice microvasculature for treating breast tumor with tunicamycin","volume":"286","author":"Banerjee","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.123.001607_bib4","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1124\/dmd.113.055996","article-title":"Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models","volume":"42","author":"Canet","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001607_bib5","doi-asserted-by":"crossref","first-page":"G825","DOI":"10.1152\/ajpgi.00145.2011","article-title":"Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition","volume":"301","author":"Charlton","year":"2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1124\/dmd.123.001607_bib6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jcmgh.2020.09.004","article-title":"Liver pyruvate kinase promotes NAFLD\/NASH in both mice and humans in a sex-specific manner","volume":"11","author":"Chella Krishnan","year":"2021","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1124\/dmd.123.001607_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.toxicon.2019.03.002","article-title":"Nonalcoholic fatty liver disease alters microcystin-LR toxicokinetics and acute toxicity","volume":"162","author":"Clarke","year":"2019","journal-title":"Toxicon"},{"key":"10.1124\/dmd.123.001607_bib8","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jhep.2014.02.021","article-title":"Synergistic interaction between genetics and disease on pravastatin disposition","volume":"61","author":"Clarke","year":"2014","journal-title":"J Hepatol"},{"key":"10.1124\/dmd.123.001607_bib9","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/liv.13362","article-title":"Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease","volume":"37","author":"Clarke","year":"2017","journal-title":"Liver Int"},{"key":"10.1124\/dmd.123.001607_bib10","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the state of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1124\/dmd.123.001607_bib11","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1158\/0008-5472.CAN-04-4662","article-title":"Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells","volume":"65","author":"Davis-Searles","year":"2005","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.123.001607_bib12","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1124\/dmd.116.071415","article-title":"Nonalcoholic steatohepatitis modulates membrane protein retrieval and insertion processes","volume":"44","author":"Dzierlenga","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001607_bib13","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/liv.12335","article-title":"Strain dependence of diet-induced NASH and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype","volume":"34","author":"Farrell","year":"2014","journal-title":"Liver Int"},{"key":"10.1124\/dmd.123.001607_bib14","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1124\/dmd.109.027466","article-title":"Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease","volume":"37","author":"Fisher","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001607_bib15","series-title":"In Vitro Drug Interaction Studies\u2014Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry.","year":"2020"},{"key":"10.1124\/dmd.123.001607_bib16","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"10.1124\/dmd.123.001607_bib17","doi-asserted-by":"crossref","first-page":"68191","DOI":"10.18632\/oncotarget.19277","article-title":"Tunicamycin induced endoplasmic reticulum stress promotes apoptosis of prostate cancer cells by activating mTORC1","volume":"8","author":"Guha","year":"2017","journal-title":"Oncotarget"},{"key":"10.1124\/dmd.123.001607_bib18","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1136\/gutjnl-2016-311526","article-title":"Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease","volume":"66","author":"Hardy","year":"2017","journal-title":"Gut"},{"key":"10.1124\/dmd.123.001607_bib72546123","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/dmd.113.054783","article-title":"Utility of Oatp1a\/1b-knockout and OATP1B1\/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein","volume":"42","author":"Higgins","year":"2014","journal-title":"Drug metabolism and disposition: the biological fate of chemicals"},{"key":"10.1124\/dmd.123.001607_bib19","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1093\/advances\/nmaa081","article-title":"Animal models of fibrosis in nonalcoholic steatohepatitis: do they reflect human disease?","volume":"11","author":"Ipsen","year":"2020","journal-title":"Adv Nutr"},{"key":"10.1124\/dmd.123.001607_bib20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12858-016-0060-2","article-title":"Altered activity patterns of transcription factors induced by endoplasmic reticulum stress","volume":"17","author":"Jiang","year":"2016","journal-title":"BMC Biochem"},{"key":"10.1124\/dmd.123.001607_bib21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12876-017-0680-z","article-title":"Fast food diet-induced non-alcoholic fatty liver disease exerts early protective effect against acetaminophen intoxication in mice","volume":"17","author":"Kim","year":"2017","journal-title":"BMC Gastroenterol"},{"key":"10.1124\/dmd.123.001607_bib22","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1124\/dmd.123.001607_bib23","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1124\/dmd.112.048272","article-title":"Interaction of silymarin flavonolignans with organic anion-transporting polypeptides","volume":"41","author":"K\u00f6ck","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001607_bib24","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.cgh.2006.12.021","article-title":"Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity","volume":"5","author":"Kolwankar","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1124\/dmd.123.001607_bib25","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/1534735407301825","article-title":"Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies","volume":"6","author":"Kroll","year":"2007","journal-title":"Integr Cancer Ther"},{"key":"10.1124\/dmd.123.001607_bib26","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/1440-1681.12102","article-title":"A high-fat diet and multiple administration of carbon tetrachloride induces liver injury and pathological features associated with non-alcoholic steatohepatitis in mice","volume":"40","author":"Kubota","year":"2013","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1124\/dmd.123.001607_bib27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.toxlet.2012.02.017","article-title":"Pharmacologic ER stress induces non-alcoholic steatohepatitis in an animal model","volume":"211","author":"Lee","year":"2012","journal-title":"Toxicol Lett"},{"key":"10.1124\/dmd.123.001607_bib28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/toxsci\/kfx253","article-title":"Asking the right questions with animal models: methionine- and choline-deficient model in predicting adverse drug reactions in human NASH","volume":"161","author":"Li","year":"2018","journal-title":"Toxicol Sci"},{"key":"10.1124\/dmd.123.001607_bib29","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/hep.30626","article-title":"Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps","volume":"70","author":"Lonardo","year":"2019","journal-title":"Hepatology"},{"key":"10.1124\/dmd.123.001607_bib30","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1002\/ptr.7049","article-title":"Hepatic organic anion transporting polypeptides mediate disposition of milk thistle flavonolignans and pharmacokinetic silymarin-drug interactions","volume":"35","author":"Lynch","year":"2021","journal-title":"Phytother Res"},{"key":"10.1124\/dmd.123.001607_bib31","doi-asserted-by":"crossref","first-page":"304","DOI":"10.4254\/wjh.v14.i2.304","article-title":"Rodent models and metabolomics in non-alcoholic fatty liver disease: what can we learn?","volume":"14","author":"Martin-Grau","year":"2022","journal-title":"World J Hepatol"},{"key":"10.1124\/dmd.123.001607_bib32","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/cts.12623","article-title":"Identification and evaluation of clinical substrates of organic anion transporting polypeptides 1B1 and 1B3","volume":"12","author":"McFeely","year":"2019","journal-title":"Clin Transl Sci"},{"key":"10.1124\/dmd.123.001607_bib33","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/mrm.27730","article-title":"Chimeric mouse model for MRI contrast agent evaluation","volume":"82","author":"Mir","year":"2019","journal-title":"Magn Reson Med"},{"key":"10.1124\/dmd.123.001607_bib34","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1124\/jpet.119.260489","article-title":"A pharmacokinetic natural product-disease-drug interaction: a double hit of silymarin and nonalcoholic steatohepatitis on hepatic transporters in a rat model","volume":"371","author":"Montonye","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.123.001607_bib35","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jnutbio.2017.01.010","article-title":"Chronic administration of saturated fats and fructose differently affect SREBP activity resulting in different modulation of Nrf2 and Nlrp3 inflammasome pathways in mice liver","volume":"42","author":"Nigro","year":"2017","journal-title":"J Nutr Biochem"},{"key":"10.1124\/dmd.123.001607_bib36","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jhep.2003.09.020","article-title":"The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance","volume":"40","author":"Rinella","year":"2004","journal-title":"J Hepatol"},{"key":"10.1124\/dmd.123.001607_bib37","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1124\/dmd.114.057976","article-title":"Evaluation of organic anion transporting polypeptide 1B1 and 1B3 humanized mice as a translational model to study the pharmacokinetics of statins","volume":"42","author":"Salphati","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001607_bib38","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1053\/gast.2002.36572","article-title":"AGA technical review on nonalcoholic fatty liver disease","volume":"123","author":"Sanyal","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1124\/dmd.123.001607_bib39","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/hep.25789","article-title":"Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis","volume":"57","author":"Savard","year":"2013","journal-title":"Hepatology"},{"key":"10.1124\/dmd.123.001607_bib40","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12876-019-1041-x","article-title":"A new method to induce nonalcoholic steatohepatitis (NASH) in mice","volume":"19","author":"Savari","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"10.1124\/dmd.123.001607_bib41","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","article-title":"Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies","volume":"7","author":"Stefan","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1124\/dmd.123.001607_bib42","doi-asserted-by":"crossref","first-page":"178","DOI":"10.4331\/wjbc.v7.i1.178","article-title":"High levels of homocysteine downregulate apolipoprotein E expression via nuclear factor kappa B","volume":"7","author":"Trusca","year":"2016","journal-title":"World J Biol Chem"},{"key":"10.1124\/dmd.123.001607_bib43","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1172\/JCI59526","article-title":"Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver","volume":"122","author":"van de Steeg","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1124\/dmd.123.001607_bib44","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1124\/dmd.108.024315","article-title":"Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1)","volume":"37","author":"van de Steeg","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001607_bib45","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1158\/1078-0432.CCR-12-2080","article-title":"Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice","volume":"19","author":"van de Steeg","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.123.001607_bib46","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/cpt.1699","article-title":"Quantitative proteomics and mechanistic modeling of transporter-mediated disposition in nonalcoholic fatty liver disease","volume":"107","author":"Vildhede","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.123.001607_bib47","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1124\/dmd.115.065979","article-title":"CYP3A activity and expression in nonalcoholic fatty liver disease","volume":"43","author":"Woolsey","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001607_bib48","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1124\/dmd.123.001607_bib49","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1124\/dmd.123.001607_bib50","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1159\/000501851","article-title":"Rodent models of nonalcoholic fatty liver disease","volume":"101","author":"Zhong","year":"2020","journal-title":"Digestion"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624011577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624011577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.123.001607","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T18:03:24Z","timestamp":1740765804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624011577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0090955624011577"],"URL":"https:\/\/doi.org\/10.1124\/dmd.123.001607","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic Effects of Different Models of Nonalcoholic Fatty Liver Disease in Transgenic Humanized OATP1B Mice","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.123.001607","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The Author(s)","name":"copyright","label":"Copyright"}]}}